Focal Laser Ablation Feasible and Safe for Treatment of Prostate Cancer
Laser heat may soon be an option to treat prostate cancer. Focal laser ablation has been found both feasible and safe in men with intermediate risk prostate cancer.
Diagnosis & Disease Information
High Remission Rates Achieved With SGN-CD33A Combination in Older Patients With AML
Deep and durable remissions were produced by the combination of SGN-CD33A and hypomethylating agents among patients with acute myeloid leukemia (AML).
DECT Trial Results Show Trastuzumab Plus Anthracyclines Are Efficacious in HER2+ Breast Cancer
Results from the DECT trial indicate that a combination of epirubicin and trastuzumab improved outcomes in patients with HER2-positive breast cancer.
Outcomes in Clinical Trials Using Precision Medicine Demonstrate Effectiveness of Modality in Patients With Cancer
A meta-analysis of hundreds of cancer clinical trials revealed that therapeutic approaches using precision medicine had improved responses and longer disease remission, even in phase I trials.
Alterations in Metabolic Pathways in Prostate Cancer Hint at Potential New Treatments
Castration-resistant prostate cancer (CRPC) has specific metabolic characteristics that could make it susceptible to new options for treatment.
Palbociclib Demonstrates Efficacy in Acute Myeloid Leukemia
The FLT3 tyrosine kinase is the most frequent mutation found in AML, and targeting CDK6 with palbociclib may be an effective strategy against AML.
Dabrafenib Plus Trametinib Continue to Show Survival Benefit in BRAF-mutant Metastatic Melanoma
The longest overall survival follow-up among randomized phase 3 trials evaluating BRAF and MEK inhibitors in patients with BRAF-mutant metastatic melanoma to date has shown the best 3-year outcome with dabrafenib plus trametinib to be in patients with normal LDH and fewer than 3 disease sites, according to a presentation at the ASCO 2016 Annual Meeting.
Utidelone Plus Capecitabine Active in Patients Heavily Pretreated for Metastatic Breast Cancer
The genetically engineered epothilone analog, utidelone, in combination with capecitabine significantly improved progression-free survival and objective response rates in patients with metastatic breast cancer who were heavily pretreated, compared with capecitabine alone, results of a phase 3 trial presented at the 2016 ASCO Annual Meeting have shown.
RET Inhibitors Active in Proportion of Patients with RET-Rearranged NSCLC
The largest database on outcomes with RET-directed therapy for RET-rearranged NSCLC to date confirms RET inhibitors are active in a proportion of patients, a study presented at the 2016 ASCO Annual Meeting has shown.
CDK4/6 Inhibitor Allows Sustained Dosing for Targeted Inhibition in 5 Solid Tumor Cancer Types
Abemaciclib, an investigational cancer therapeutic, showed durable clinical activity as a continuous single-agent therapy, according to results of a phase 1 trial with 5 tumor-specific cohorts.
- Loading...
Loading...
Loading... 
Loading...